Laufende Studien

FOURLIGHT-3
fortgeschritten/metastasiert
HR+/HER2- Mammakarzinom
Phase III

An interventional, open-label, randomized, multicenter phase 3 study of PF-07220060 plus letrozole compared to CDK4/6 inhibitor plus letrozole in participants over 18 years of age with hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer who have not received any prior systemic anticancer treatment for advanced/metastatic disease (FourLight-3)

ASCENT-05
post-neoadjuvant
Triple negatives Mammakarzinom
Phase III

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

CAMBRIA-2
adjuvant
HR+/HER2- Mammakarzinom
Phase III

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

ADAPT late
adjuvant
HR+/HER2- Mammakarzinom
Phase III

Eine randomisierte, offene, adjuvante, an dynamischen Markern adjustierte, personalisierte Therapiestudie der Phase-III zum Vergleich der Therapie von Abemaciclib plus endokriner Standardtherapie gegenüber alleiniger adjuvanter endokriner Standardtherapie bei Hormonrezeptor-positivem, HER2-Rezeptor negativem Brustkrebs im Frühstadium mit klinisch oder genomisch hohem Risiko für ein Spätrezidiv

GeparPiPPa
neoadjuvant
HER2+/HR+/PIK3CA mutiertes Mammakarzinom
Phase II

A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer

eVOLVE-Lung02
metastasiertes NSCLC
PD-L1 Status <50%
1^st line Therapie
Phase III

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)

TROPION-Lung10
Stadium IIIB, IIIC, IV NSCLC
PD-L1 TC ≥50%
1^st line Therapie
Phase III

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

BRUIN-CLL-211
r/r CLL/SLL
1-3 Vortherapien inklusive cBTKi
Phase II

A Phase 2, Open-label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refactory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

BELLWAVE-011
CLL/SLL
1^st line Therapie
Phase III

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CLL 16
Hochrisiko CLL
1^st line Therapie
Phase III

A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk (17P-deletion, TP53-mutation or Complex Karyotype) Chronic Lymphatic Leukemia (CLL)

GOLSEEK-1
Hochrisiko DLBCL
1^st line Therapie
Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma

ELEMENT-MDS
Myelodysplastisches Syndrom
Neu diagnostiziert, ESA naiv
Phase III

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)

Deutschsprachige Informationen für Patienten und Angehörige finden Sie hier